Sutro Biopharma (STRO) Stock Forecast, Price Target & Predictions
STRO Stock Forecast
Sutro Biopharma stock forecast is as follows: an average price target of $11.14 (represents a 340.32% upside from STRO’s last price of $2.53) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
STRO Price Target
The average price target for Sutro Biopharma (STRO) is $11.14 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $8.00. This represents a potential 340.32% upside from STRO's last price of $2.53.
STRO Analyst Ratings
According to 7 Wall Street analysts, Sutro Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for STRO stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Sutro Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 11, 2024 | Tazeen Ahmad | Bank of America Securities | $12.00 | $3.60 | 232.87% | 374.31% |
| Oct 11, 2024 | Andrew Fein | H.C. Wainwright | $12.00 | $3.61 | 232.41% | 374.31% |
| Aug 16, 2024 | Asthika Goonewardene | Truist Financial | $15.00 | $4.21 | 256.29% | 492.89% |
| May 14, 2024 | James Shin | Deutsche Bank | $10.00 | $4.34 | 130.41% | 295.26% |
| May 14, 2024 | David Nierengarten | Wedbush | $8.00 | $4.23 | 89.13% | 216.21% |
| Apr 03, 2024 | Jay Olson | Oppenheimer | $10.00 | $5.09 | 96.46% | 295.26% |
| Apr 03, 2024 | Edward Tenthoff | Piper Sandler | $11.00 | $5.09 | 116.11% | 334.78% |
| Apr 02, 2024 | Asthika Goonewardene | Truist Financial | $18.00 | $5.09 | 253.63% | 611.46% |
| Jan 13, 2023 | - | Truist Financial | $25.00 | $8.13 | 207.31% | 888.14% |
| Jan 10, 2023 | - | Piper Sandler | $18.00 | $8.29 | 117.13% | 611.46% |
The latest Sutro Biopharma stock forecast, released on Oct 11, 2024 by Tazeen Ahmad from Bank of America Securities, set a price target of $12.00, which represents a 232.87% increase from the stock price at the time of the forecast ($3.60), and a 374.31% increase from STRO last price ($2.53).
Sutro Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 8 |
| Avg Price Target | - | $12.00 | $12.00 |
| Last Closing Price | $2.53 | $2.53 | $2.53 |
| Upside/Downside | -100.00% | 374.31% | 374.31% |
In the current month, the average price target of Sutro Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sutro Biopharma's last price of $2.53. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 11, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Oct 11, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Oct 11, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 11, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Oct 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 16, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Sep 16, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Sutro Biopharma's last stock rating was published by H.C. Wainwright on Oct 11, 2024. The company gave STRO a "Underperform" rating, the same as its previous rate.
Sutro Biopharma Financial Forecast
Sutro Biopharma Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $113.72M | $16.92M | $10.41M | $12.67M | $8.63M | $25.15M | $28.10M | $5.90M | $10.65M | $8.52M | $28.05M | $14.66M | $8.28M | $17.82M | $9.47M | $7.15M | $11.30M | $12.28M |
| Avg Forecast | $9.01M | $1.63M | $15.08M | $13.90M | $8.92M | $10.88M | $10.84M | $10.80M | $12.15M | $15.29M | $21.02M | $12.07M | $57.36M | $13.01M | $12.56M | $12.13M | $14.52M | $35.71M | $16.01M | $10.46M | $11.81M | $8.97M | $13.29M | $4.80M | $8.27M | $7.29M | $6.96M | $10.70M | $9.95M | $9.86M |
| High Forecast | $12.65M | $2.28M | $21.19M | $19.53M | $12.53M | $15.29M | $15.23M | $15.17M | $22.22M | $21.48M | $21.02M | $12.07M | $83.82M | $13.20M | $17.64M | $17.04M | $20.39M | $35.71M | $16.01M | $10.46M | $11.81M | $8.97M | $13.29M | $4.80M | $8.27M | $7.29M | $6.96M | $10.70M | $9.95M | $9.86M |
| Low Forecast | $5.46M | $984.38K | $9.13M | $8.42M | $5.40M | $6.59M | $6.57M | $6.54M | $2.35M | $9.26M | $21.02M | $12.07M | $28.30M | $12.81M | $7.61M | $7.35M | $8.79M | $35.71M | $16.01M | $10.46M | $11.81M | $8.97M | $13.29M | $4.80M | $8.27M | $7.29M | $6.96M | $10.70M | $9.95M | $9.86M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 9 | 13 | 8 | 8 | 9 | 12 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.98% | 1.30% | 0.83% | 1.04% | 0.59% | 0.70% | 1.76% | 0.56% | 0.90% | 0.95% | 2.11% | 3.05% | 1.00% | 2.45% | 1.36% | 0.67% | 1.14% | 1.25% |
Sutro Biopharma's average Quarter revenue forecast for Mar 24 based on 4 analysts is $12.07M, with a low forecast of $12.07M, and a high forecast of $12.07M. STRO's average Quarter revenue forecast represents a -89.38% decrease compared to the company's last Quarter revenue of $113.72M (Dec 23).
Sutro Biopharma EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 9 | 13 | 8 | 8 | 9 | 12 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $44.88M | $-44.01M | $-46.18M | $-39.68M | $-45.57M | $-18.76M | $-17.79M | $-37.69M | $-36.81M | $-28.96M | $-4.18M | $-28.21M | $-60.62M | $20.42M | $33.89M | $-17.44M | $-13.57M | $-10.54M |
| Avg Forecast | $-7.20M | $-1.30M | $-12.06M | $-11.11M | $-7.13M | $-8.70M | $-8.67M | $-8.64M | $-9.72M | $-12.23M | $-16.81M | $-41.46M | $-45.86M | $-10.40M | $-10.04M | $-37.69M | $-32.28M | $-32.40M | $-14.52M | $-34.26M | $-10.72M | $-8.14M | $-12.06M | $-25.39M | $-7.50M | $-6.61M | $-6.32M | $-13.65M | $-9.03M | $-8.94M |
| High Forecast | $-4.36M | $-787.07K | $-7.30M | $-6.73M | $-4.32M | $-5.27M | $-5.25M | $-5.23M | $-1.88M | $-7.40M | $-16.81M | $-33.17M | $-22.63M | $-10.24M | $-6.08M | $-30.15M | $-25.82M | $-32.40M | $-14.52M | $-27.41M | $-10.72M | $-8.14M | $-12.06M | $-20.31M | $-7.50M | $-6.61M | $-6.32M | $-10.92M | $-9.03M | $-8.94M |
| Low Forecast | $-10.12M | $-1.83M | $-16.94M | $-15.61M | $-10.02M | $-12.22M | $-12.18M | $-12.13M | $-17.77M | $-17.18M | $-16.81M | $-49.75M | $-67.02M | $-10.55M | $-14.11M | $-45.23M | $-38.73M | $-32.40M | $-14.52M | $-41.12M | $-10.72M | $-8.14M | $-12.06M | $-30.47M | $-7.50M | $-6.61M | $-6.32M | $-16.38M | $-9.03M | $-8.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.98% | 4.23% | 4.60% | 1.05% | 1.41% | 0.58% | 1.22% | 1.10% | 3.43% | 3.56% | 0.35% | 1.11% | 8.08% | -3.09% | -5.37% | 1.28% | 1.50% | 1.18% |
4 analysts predict STRO's average Quarter EBITDA for Mar 24 to be $-41.46M, with a high of $-33.17M and a low of $-49.75M. This is -192.37% lower than Sutro Biopharma's previous annual EBITDA (Dec 23) of $44.88M.
Sutro Biopharma Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 9 | 13 | 8 | 8 | 9 | 12 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $31.07M | $-49.28M | $-38.52M | $-50.05M | $-37.09M | $-17.77M | $-26.01M | $-39.09M | $-38.13M | $-30.90M | $-6.15M | $-30.36M | $-59.54M | $17.14M | $29.87M | $-19.59M | $-14.79M | $-12.91M |
| Avg Forecast | $-49.77M | $-51.68M | $-51.17M | $-54.84M | $-76.79M | $-65.96M | $-65.63M | $-68.75M | $-68.14M | $-60.27M | $-64.95M | $-44.33M | $-22.26M | $-60.39M | $-60.10M | $-40.30M | $-33.43M | $-23.45M | $-52.33M | $-36.63M | $-61.66M | $-52.90M | $-33.62M | $-27.32M | $-46.30M | $-41.19M | $-52.29M | $-15.34M | $-56.38M | $-51.31M |
| High Forecast | $-24.25M | $-25.19M | $-24.94M | $-26.73M | $-37.43M | $-32.15M | $-31.99M | $-64.85M | $-58.77M | $-29.37M | $-31.65M | $-35.46M | $-17.10M | $-29.43M | $-29.29M | $-32.24M | $-26.74M | $-23.45M | $-52.33M | $-29.31M | $-61.66M | $-52.90M | $-33.62M | $-21.86M | $-46.30M | $-41.19M | $-52.29M | $-12.27M | $-56.38M | $-51.31M |
| Low Forecast | $-75.96M | $-78.88M | $-78.11M | $-83.70M | $-117.21M | $-100.68M | $-100.18M | $-71.88M | $-81.77M | $-91.99M | $-99.14M | $-53.19M | $-25.51M | $-92.17M | $-91.73M | $-48.36M | $-40.11M | $-23.45M | $-52.33M | $-43.96M | $-61.66M | $-52.90M | $-33.62M | $-32.79M | $-46.30M | $-41.19M | $-52.29M | $-18.40M | $-56.38M | $-51.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -1.40% | 0.82% | 0.64% | 1.24% | 1.11% | 0.76% | 0.50% | 1.07% | 0.62% | 0.58% | 0.18% | 1.11% | 1.29% | -0.42% | -0.57% | 1.28% | 0.26% | 0.25% |
Sutro Biopharma's average Quarter net income forecast for Mar 24 is $-44.33M, with a range of $-53.19M to $-35.46M. STRO's average Quarter net income forecast represents a -242.69% decrease compared to the company's last Quarter net income of $31.07M (Dec 23).
Sutro Biopharma SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 9 | 13 | 8 | 8 | 9 | 12 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $15.07M | $15.27M | $15.00M | $15.51M | $14.72M | $14.64M | $15.14M | $15.04M | $15.76M | $16.59M | $12.54M | $11.11M | $10.38M | $9.08M | $8.64M | $8.71M | $8.70M | $8.12M |
| Avg Forecast | $6.87M | $1.24M | $11.51M | $10.61M | $6.81M | $8.30M | $8.27M | $8.24M | $9.27M | $11.67M | $16.04M | $9.21M | $43.77M | $9.92M | $9.58M | $9.26M | $13.82M | $26.93M | $12.07M | $7.89M | $8.91M | $6.76M | $10.03M | $3.62M | $6.24M | $5.49M | $5.25M | $6.82M | $7.51M | $7.43M |
| High Forecast | $9.66M | $1.74M | $16.17M | $14.90M | $9.56M | $11.66M | $11.62M | $11.58M | $16.96M | $16.39M | $16.04M | $9.21M | $63.96M | $10.07M | $13.46M | $13.00M | $16.59M | $26.93M | $12.07M | $7.89M | $8.91M | $6.76M | $10.03M | $3.62M | $6.24M | $5.49M | $5.25M | $8.18M | $7.51M | $7.43M |
| Low Forecast | $4.16M | $751.11K | $6.97M | $6.42M | $4.12M | $5.03M | $5.01M | $4.99M | $1.79M | $7.07M | $16.04M | $9.21M | $21.59M | $9.78M | $5.80M | $5.61M | $11.06M | $26.93M | $12.07M | $7.89M | $8.91M | $6.76M | $10.03M | $3.62M | $6.24M | $5.49M | $5.25M | $5.46M | $7.51M | $7.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.34% | 1.54% | 1.57% | 1.68% | 1.06% | 0.54% | 1.25% | 1.91% | 1.77% | 2.45% | 1.25% | 3.07% | 1.66% | 1.65% | 1.65% | 1.28% | 1.16% | 1.09% |
Sutro Biopharma's average Quarter SG&A projection for Mar 24 is $9.21M, based on 4 Wall Street analysts, with a range of $9.21M to $9.21M. The forecast indicates a -38.88% fall compared to STRO last annual SG&A of $15.07M (Dec 23).
Sutro Biopharma EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 9 | 13 | 8 | 8 | 9 | 12 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.51 | $-0.81 | $-0.00 | $-0.85 | $-0.73 | $-0.34 | $-0.55 | $-0.84 | $-0.83 | $-0.67 | $-0.13 | $-0.66 | $-1.61 | $0.46 | $1.00 | $-0.84 | $-0.64 | $-0.56 |
| Avg Forecast | $-0.61 | $-0.63 | $-0.62 | $-0.67 | $-0.94 | $-0.80 | $-0.80 | $-0.84 | $-0.83 | $-0.73 | $-0.79 | $-0.92 | $-0.27 | $-0.74 | $-0.73 | $-0.78 | $-0.62 | $-0.29 | $-0.64 | $-0.76 | $-0.76 | $-0.65 | $-0.41 | $-0.62 | $-0.57 | $-0.51 | $-0.64 | $-0.69 | $-0.69 | $-0.63 |
| High Forecast | $-0.30 | $-0.31 | $-0.30 | $-0.33 | $-0.46 | $-0.39 | $-0.39 | $-0.79 | $-0.72 | $-0.36 | $-0.39 | $-0.45 | $-0.21 | $-0.36 | $-0.36 | $-0.38 | $-0.30 | $-0.29 | $-0.64 | $-0.76 | $-0.76 | $-0.65 | $-0.41 | $-0.62 | $-0.57 | $-0.51 | $-0.64 | $-0.69 | $-0.69 | $-0.63 |
| Low Forecast | $-0.93 | $-0.96 | $-0.95 | $-1.02 | $-1.43 | $-1.23 | $-1.22 | $-0.88 | $-1.00 | $-1.12 | $-1.21 | $-1.41 | $-0.31 | $-1.12 | $-1.12 | $-1.20 | $-0.95 | $-0.29 | $-0.64 | $-0.76 | $-0.76 | $-0.65 | $-0.41 | $-0.62 | $-0.57 | $-0.51 | $-0.64 | $-0.69 | $-0.69 | $-0.63 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -1.88% | 1.10% | 0.00% | 1.08% | 1.18% | 1.18% | 0.85% | 1.11% | 1.09% | 1.03% | 0.31% | 1.06% | 2.83% | -0.91% | -1.55% | 1.22% | 0.92% | 0.89% |
According to 4 Wall Street analysts, Sutro Biopharma's projected average Quarter EPS for Mar 24 is $-0.92, with a low estimate of $-1.41 and a high estimate of $-0.45. This represents a -280.70% decrease compared to STRO previous annual EPS of $0.51 (Dec 23).
Sutro Biopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HLVX | HilleVax | $1.82 | $32.00 | 1658.24% | Hold |
| AVTE | Aerovate Therapeutics | $2.61 | $13.00 | 398.08% | Hold |
| OPT | Opthea | $3.13 | $14.00 | 347.28% | Buy |
| STRO | Sutro Biopharma | $2.53 | $11.14 | 340.32% | Buy |
| LRMR | Larimar Therapeutics | $6.13 | $20.33 | 231.65% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| MLYS | Mineralys Therapeutics | $11.87 | $30.00 | 152.74% | Buy |
| ANAB | AnaptysBio | $21.17 | $52.00 | 145.63% | Buy |
| SNDX | Syndax Pharmaceuticals | $15.60 | $34.30 | 119.87% | Buy |
| REPL | Replimune Group | $11.05 | $24.20 | 119.00% | Buy |
| KROS | Keros Therapeutics | $53.84 | $102.60 | 90.56% | Buy |
| IDYA | IDEAYA Biosciences | $26.60 | $46.58 | 75.11% | Buy |
| MRUS | Merus | $44.36 | $76.67 | 72.84% | Buy |
| MGTX | MeiraGTx | $5.92 | $9.00 | 52.03% | Buy |
| PCVX | Vaxcyte | $88.39 | $124.00 | 40.29% | Buy |
| CNTA | Centessa Pharmaceuticals | $18.19 | $23.25 | 27.82% | Buy |